---
title: 'ESR Essentials: response assessment criteria in oncologic imaging-practice
  recommendations by the European Society of Oncologic Imaging'
date: '2024-08-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39136705/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240813182518&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Assessing the response to oncological treatments is paramount for determining
  the prognosis and defining the best treatment for each patient. Several biomarkers,
  including imaging, can be used, but standardization is fundamental for consistency
  and reliability. Tumor response evaluation criteria have been defined by international
  groups for application in pharmaceutical clinical trials evaluating new drugs or
  therapeutic strategies. RECIST 1.1 criteria are exclusively based on ...
disable_comments: true
---
Assessing the response to oncological treatments is paramount for determining the prognosis and defining the best treatment for each patient. Several biomarkers, including imaging, can be used, but standardization is fundamental for consistency and reliability. Tumor response evaluation criteria have been defined by international groups for application in pharmaceutical clinical trials evaluating new drugs or therapeutic strategies. RECIST 1.1 criteria are exclusively based on ...